Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 ?m.

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: A transparent electrode material including a conductive layer having an active surface and a second surface, and an adjacent base layer, wherein: ? the conductive layer includes a conductive network formed by metallic nanowires and carbon nanotubes encapsulated in a conductive material; ? the second surface of the conductive layer has encapsulated nanowires and/or nanotubes projecting therefrom; and ? the encapsulated nanowires and/or nanotubes projecting from the second surface of the conductive layer are embedded in the adjacent base layer; whereby the active surface of the conductive layer is smooth and electrically active, and the transparent electrode material has a sheet resistance less than 50 ?/sq and a transparency greater than 70%.

Abstract: Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 ?m.

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: The present invention provides a method for manufacturing a photochromic article having a photochromic compound containing layer. The method includes the step of coating a casting face of at least one mold section with a photochromic host layer. The photochromic host layer is treated to minimize damage during subsequent steps, and a mold is then assembled so that it includes the mold section having the photochromic host layer. The mold is then filled with a photochromic article monomer composition and the monomer composition is subsequently cured to form a photochromic article substrate adhered to the photochromic host layer. The photochromic compound is introduced into the photochromic host layer.

Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

Abstract: Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be phosphoric acid or sulphuric acid.

Abstract: A method and system for optimizing the dispensing of aerosol medicaments by “pulsing” a total dose volume as a series of shorter, low volume bursts is described. Aerosol performance when metering at a low volume e.g. <10 ?L is enhanced by an increase in the fine particle fraction, particularly when pulsing a dose to achieve a high total dose volume. By utilising a solenoid valve, the system can deliver a medicament in a single low volume pulse; or in multiple low volume pulses. Performance can be tailored to obtain a preferred fine particle dose and fraction. By manipulating the solenoid valve timings, a single formulation with a concentration X may be used to provide a range of doses. A minimum interval between pulses to achieve separate “non-interacting” plumes which allow keeping total inhalation time comparable to a conventional single dose MDI actuation is also described.

Abstract: A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant.

Abstract: An actuator for a metered-dose inhaler is provided. The actuator comprises a housing having a mouthpiece portion and a canister receiving portion configured to receive a canister. The actuator further comprises a member disposed within the housing and defining a valve stem receptacle configured to receive a valve stem of the canister. An orifice is formed in the member, which is in fluid communication with the valve stem receptacle and extending to a face of the member opposite to the valve stem receptacle. A longitudinal axis of the orifice is aligned with a longitudinal axis of the valve stem receptacle. At least one air inlet opening is provided in an outer shell of the housing so as to be spaced from an opening for receiving the canister and a mouthpiece opening.

Abstract: A metered-dose inhaler includes at least one vessel and an actuator for receiving the at least one vessel. The at least one vessel includes a first reservoir containing a first formulation and a second reservoir containing a second formulation. The metered-dose inhaler is actuable when the at least one vessel is received by the actuator. The metered-dose inhaler is configured to simultaneously deliver a first metered dose of the first formulation and a second metered dose of the second formulation upon actuation.

Abstract: The present invention provides a method for manufacturing a photochromic article having a photochromic compound containing layer. The method includes the step of coating a casting face of at least one mould section with a photochromic host layer. The photochromic host layer is treated to minimise damage during subsequent steps, and a mould is then assembled so that it includes the mould section having the photochromic host layer. The mould is then filled with a photochromic article monomer composition and the monomer composition is subsequently cured to form a photochromic article substrate adhered to the photochromic host layer. The photochromic compound is introduced into the photochromic host layer.

Abstract: The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting ?2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurized metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Abstract: A method of forming a coated optical element is disclosed herein. The method uses a mold having first and second mold sections that will form front and back surfaces of the optical element, one of the mold sections having a casting face.

Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

Abstract: A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant.

Abstract: The invention relates to a photochromic polymeric composition comprising a polymer matrix and a photochromic compound which is an adduct comprising a photochromic moiety and at least one pendant oligomer group to provide a rate of fade of the photochromic polymeric composition which is significantly changed when compared with the corresponding composition comprising the photochromic compound without said pendent oligomer. The invention also relates to a photochromic compound which is an adduct comprising a photochromic moiety and at least one pendent oligomer.